INS and diabetes mellitus: The planned TAME (targeting aging with metformin) trial will test for the first time whether metformin, a glucose-lowering drug mainly promoting insulin sensitivity in the liver, is able to decrease the incidence of age-related diseases in patients with at least one age-related disease and without diabetes [107].